225Ac-anti-TROP2 antibody (Convergent Therapeutics)

N/A

Report date: 2026/04/16 20:00:17

Base Information

Drug Name225Ac-anti-TROP2 antibody (Convergent Therapeutics)

Drug Alias NameN/A

ClassificationRadiation-emitting products > Nuclides > Actinium > 225AcRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive therapeutic agent +[4]

Mechanisms of ActionAnti-Trop-2

TargetsTumor-associated calcium signal transducer 2

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesConvergent Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesConvergent Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A